April 12, 2011 11:08 ET

Superior Outcomes Are Driving Wider Adoption of Orthobiologics

ROCKVILLE, MD--(Marketwire - Apr 12, 2011) - has announced the addition of GBI Research's new report "Orthobiologics to 2016 - Alternatives to Surgery and Superior Outcomes are Driving Wider Adoption of Orthobiologics" to their collection of Biotechnology market reports. For more information, visit

The global orthobiologics market was valued at $4.3 billion in 2009, and is forecast to reach $9.6 billion in 2016, which represents a compound annual growth rate (CAGR) of 12%. Bone graft substitutes will remain the largest segment in the market, with a value of $5.3 billion by 2016. Growth in the market is primarily being driven by the increasing incidence of arthritis, an increasingly elderly population, and higher obesity rates.

Globally, about 350 million people have arthritis, and more than half of those with arthritis are under 65 years of age. Also, advances in technology, such as the development of nanotechnology coatings for use in wear-resistant orthopedic devices, and injectable bones, which are biodegradable and can fill any cavity shape, taking on similar characteristics to normal bone, are expected to drive the market in the near future.

The orthobiologics product pipeline is strong, with about 134 products making their way to market. These products are aimed at reducing rejection rates, stimulating the growth of bone and improving patient outcomes. The advantages offered and the simplicity in use of many of these pipeline products is expected to increase their uptake. Nanotechnology will be the key driver of growth in the orthobiologics market in the near future.

There are products in the pipeline which have nanotechnology coatings, for use in wear-resistant orthopedic devices, specifically for spinal implants. Due to this coating, the products offer a higher level of durability, thus increasing demand for them. Also, companies are developing injectable bones which are biodegradable, and are able to stabilize fractured bones, offering superior strength, rapid setting and mouldable properties.

Products offering greater durability, reductions in inflammation, and which improve the quality of life, are expected to drive future demand for orthobiologics.

For more information, visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact